Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 13 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.82 Insider Own3.87% Shs Outstand6.01M Perf Week2.56%
Market Cap2.16M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float5.78M Perf Month-10.82%
Income-6.36M PEG- EPS next Q- Inst Own2.87% Short Float0.41% Perf Quarter3.15%
Sales0.00M P/S- EPS this Y- Inst Trans10.65% Short Ratio0.13 Perf Half Y7.66%
Book/sh2.12 P/B0.17 EPS next Y- ROA-43.37% Short Interest0.02M Perf Year-90.32%
Cash/sh1.82 P/C0.20 EPS next 5Y20.00% ROE-51.38% 52W Range0.26 - 5.47 Perf YTD-20.88%
Dividend Est.- P/FCF- EPS past 5Y21.08% ROI-49.84% 52W High-93.42% Beta0.72
Dividend TTM- Quick Ratio6.34 Sales past 5Y-20.00% Gross Margin- 52W Low38.46% ATR (14)0.03
Dividend Ex-Date- Current Ratio6.34 EPS Y/Y TTM77.51% Oper. Margin0.00% RSI (14)46.73 Volatility10.31% 9.26%
Employees8 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price1.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q78.56% Payout- Rel Volume0.09 Prev Close0.36
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume180.64K Price0.36
SMA20-3.31% SMA50-4.95% SMA200-15.12% Trades Volume15,872 Change0.00%
Date Action Analyst Rating Change Price Target Change
May-22-20Downgrade B. Riley FBR Buy → Neutral $11 → $8
Feb-04-20Initiated Craig Hallum Buy $18
Jan-30-20Resumed Cantor Fitzgerald Overweight $9 → $14
Dec-02-19Initiated Canaccord Genuity Buy
Dec-12-18Initiated B. Riley FBR Buy $28
Aug-02-18Reiterated Maxim Group Buy $30 → $27
Jul-13-18Initiated Stifel Buy $35
Jul-12-18Initiated Cantor Fitzgerald Overweight $59
Jun-12-18Reiterated H.C. Wainwright Buy $24 → $43
Mar-15-18Upgrade Maxim Group Hold → Buy $14
Apr-10-24 06:30AM
Apr-05-24 09:53AM
Apr-04-24 05:06PM
Mar-15-24 09:00AM
Nov-21-23 07:32AM
04:32PM Loading…
Nov-20-23 04:32PM
Sep-26-23 08:30AM
Sep-22-23 04:05PM
Aug-10-23 11:08AM
Jul-14-23 09:20AM
Jul-10-23 08:00AM
Jun-01-23 08:05AM
May-09-23 07:00AM
May-04-23 04:00PM
05:00PM Loading…
Mar-29-23 05:00PM
Feb-08-23 08:00AM
Jan-06-23 06:34AM
Jan-04-23 08:00AM
Dec-14-22 05:00PM
Sep-14-22 12:00PM
Aug-04-22 08:00AM
Jul-18-22 11:43AM
Jul-13-22 10:53AM
Jul-07-22 10:18AM
Jun-17-22 04:15PM
Jun-15-22 10:47AM
May-17-22 08:00AM
07:00AM Loading…
May-02-22 07:00AM
Apr-28-22 07:00AM
Apr-26-22 08:30AM
Mar-29-22 10:18AM
Jan-11-22 07:30AM
Jan-10-22 07:30AM
Nov-08-21 07:30AM
Nov-01-21 12:38PM
Oct-11-21 08:00AM
Aug-24-21 12:03PM
Aug-19-21 11:49AM
Aug-16-21 08:00AM
Aug-11-21 12:48PM
Aug-10-21 03:41PM
Aug-05-21 07:00AM
Aug-03-21 04:49AM
Aug-02-21 09:26AM
Jul-29-21 08:30AM
Jun-04-21 06:57AM
May-13-21 07:50AM
May-06-21 08:30AM
May-03-21 08:30AM
Mar-19-21 07:23AM
Mar-18-21 07:00AM
Mar-16-21 08:00AM
Mar-11-21 08:30AM
Feb-16-21 09:29AM
Feb-11-21 11:16AM
Feb-04-21 01:30AM
Jan-26-21 08:00AM
Jan-19-21 08:00AM
Dec-17-20 07:00AM
Dec-04-20 09:08AM
Nov-12-20 07:00AM
Nov-10-20 08:40AM
Nov-09-20 08:00AM
Nov-05-20 08:30AM
Oct-20-20 08:31AM
Sep-10-20 08:49AM
Aug-06-20 07:00AM
Jul-30-20 08:30AM
Jul-22-20 10:34AM
Jul-14-20 05:31PM
Jul-06-20 07:55AM
Jun-26-20 06:42AM
Jun-10-20 08:34AM
May-14-20 05:31PM
May-07-20 08:30AM
May-02-20 09:36AM
Mar-26-20 09:40PM
Mar-12-20 07:00AM
Mar-05-20 08:30AM
Feb-28-20 09:30AM
Feb-05-20 04:11PM
Jan-03-20 08:25AM
Dec-14-19 07:21PM
Dec-04-19 09:26AM
Nov-29-19 08:41AM
Nov-08-19 10:57PM
Nov-06-19 07:00AM
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.